Vemurafenib-associated neutrophilic panniculitis in a patient with metastatic amelanotic melanoma presenting as cancer of unknown primary origin

被引：2

作者：

Weng, Yu-Ching ^{[1
]}

Chiu, Chien-Shan ^{[1
]}

Lin, Tseng-Hsi ^{[2
,3
,4
]}

Shen, Jui-Lung ^{[1
]}

Yang, Chii-Shuenn ^{[5
]}

Chen, Joe-Bin ^{[6
]}

机构：

[1] Taichung Vet Gen Hosp, Dept Dermatol, Taichung 40705, Taiwan

[2] Taichung Vet Gen Hosp, Dept Pathol & Lab Med, Div Transfus Med, Taichung 40705, Taiwan

[3] Taichung Vet Gen Hosp, Dept Internal Med, Div Hematol Oncol, Taichung 40705, Taiwan

[4] Chung Shan Med Univ, Sch Med, Dept Internal Med, Taichung, Taiwan

[5] Taichung Vet Gen Hosp, Dept Pathol, Taichung 40705, Taiwan

[6] Taichung Vet Gen Hosp, Dept Surg, Div Colorectal Surg, 1650,Sect 4,Taiwan Blvd, Taichung 40705, Taiwan

来源：

DERMATOLOGICA SINICA | 2016年 / 34卷 / 02期

关键词：

BRAF inhibitor; drug reaction; erythema nodosum; melanoma; panniculitis; vemurafenib; BRAF INHIBITORS; THERAPY;

D O I：

10.1016/j.dsi.2015.08.002

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

The treatment of metastatic melanoma is challenging. BRAF gene mutation is found in 40-60% of melanoma cases, the most common being the V600E mutation. Vemurafenib was approved by the Food and Drug Administration in 2011 as target therapy for the treatment with BRAF V600 mutation-positive metastatic melanoma. We report a case of metastatic amelanotic melanoma with unknown primary cancer as the initial presentation. The patient presented with neutrophilic septal panniculitis 1 week after vemurafenib treatment, which is a rare cutaneous toxicity of BRAF inhibitor. We also review the current literature on management of BRAF inhibitor-related adverse skin effects. Copyright (C) 2015, Taiwanese Dermatological Association. Published by Elsevier Taiwan LLC.

引用

页码：88 / 91

页数：4

共 17 条

[1] Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation [J].

Chapman, Paul B. ;

Hauschild, Axel ;

Robert, Caroline ;

Haanen, John B. ;

Ascierto, Paolo ;

Larkin, James ;

Dummer, Reinhard ;

Garbe, Claus ;

Testori, Alessandro ;

Maio, Michele ;

Hogg, David ;

Lorigan, Paul ;

Lebbe, Celeste ;

Jouary, Thomas ;

Schadendorf, Dirk ;

Ribas, Antoni ;

O'Day, Steven J. ;

Sosman, Jeffrey A. ;

Kirkwood, John M. ;

Eggermont, Alexander M. M. ;

Dreno, Brigitte ;

Nolop, Keith ;

Li, Jiang ;

Nelson, Betty ;

Hou, Jeannie ;

Lee, Richard J. ;

Flaherty, Keith T. ;

McArthur, Grant A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2507-2516

[2] Panniculitis in Patients Treated With BRAF Inhibitors: A Case Series [J].

Choy, Bonita ;

Chou, Shaun ;

Anforth, Rachael ;

Fernandez-Penas, Pablo .

AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2014, 36 (06) :493-497

[3] Mutations of the BRAF gene in human cancer [J].

Davies, H ;

Bignell, GR ;

Cox, C ;

Stephens, P ;

Edkins, S ;

Clegg, S ;

Teague, J ;

Woffendin, H ;

Garnett, MJ ;

Bottomley, W ;

Davis, N ;

Dicks, N ;

Ewing, R ;

Floyd, Y ;

Gray, K ;

Hall, S ;

Hawes, R ;

Hughes, J ;

Kosmidou, V ;

Menzies, A ;

Mould, C ;

Parker, A ;

Stevens, C ;

Watt, S ;

Hooper, S ;

Wilson, R ;

Jayatilake, H ;

Gusterson, BA ;

Cooper, C ;

Shipley, J ;

Hargrave, D ;

Pritchard-Jones, K ;

Maitland, N ;

Chenevix-Trench, G ;

Riggins, GJ ;

Bigner, DD ;

Palmieri, G ;

Cossu, A ;

Flanagan, A ;

Nicholson, A ;

Ho, JWC ;

Leung, SY ;

Yuen, ST ;

Weber, BL ;

Siegler, HF ;

Darrow, TL ;

Paterson, H ;

Marais, R ;

Marshall, CJ ;

Wooster, R .

NATURE, 2002, 417 (6892) :949-954

[4] Intermittent dosing with vemurafenib in BRAF V600E-mutant melanoma: review of a case series [J].

Dooley, Andrew J. ;

Gupta, Avinash ;

Bhattacharyya, Madhumita ;

Middleton, Mark R. .

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2014, 6 (06) :262-266

[5] The MAPK pathway in melanoma [J].

Fecher, Leslie A. ;

Arnaravadi, Ravi K. ;

Flaherty, Keith T. .

CURRENT OPINION IN ONCOLOGY, 2008, 20 (02) :183-189

[6] Inhibition of Mutated, Activated BRAF in Metastatic Melanoma [J].

Flaherty, Keith T. ;

Puzanov, Igor ;

Kim, Kevin B. ;

Ribas, Antoni ;

McArthur, Grant A. ;

Sosman, Jeffrey A. ;

O'Dwyer, Peter J. ;

Lee, Richard J. ;

Grippo, Joseph F. ;

Nolop, Keith ;

Chapman, Paul B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (09) :809-819

[7] Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib [J].

Kim, Gene H. ;

Levy, Alan ;

Compoginis, Goli .

JOURNAL OF CUTANEOUS PATHOLOGY, 2013, 40 (07) :667-669

[8]

Kotteas EA, 2009, IN VIVO, V23, P487

[9] Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature [J].

Moessner, R. ;

Zimmer, L. ;

Berking, C. ;

Hoeller, C. ;

Loquai, C. ;

Richtig, E. ;

Kaehler, K. C. ;

Hassel, J. C. ;

Gutzmer, R. ;

Ugurel, S. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2015, 29 (09) :1797-1806

[10] Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma [J].

Pattanaprichakul, Penvadee ;

Tetzlaff, Michael T. ;

Lapolla, Whitney J. ;

Torres-Cabala, Carlos A. ;

Duvic, Madeleine ;

Prieto, Victor G. ;

Tsai, Kenneth Y. ;

Curry, Jonathan L. .

JOURNAL OF CUTANEOUS PATHOLOGY, 2014, 41 (03) :326-328

← 1 2 →